Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Sovleplenib acetate by Hutchison MediPharma for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Sovleplenib acetate is under clinical development by Hutchison MediPharma and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL)....
Sovleplenib acetate by Hutchison MediPharma for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
Sovleplenib acetate is under clinical development by Hutchison MediPharma and currently in Phase I for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)....
Sovleplenib acetate by Hutchison MediPharma for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Sovleplenib acetate is under clinical development by Hutchison MediPharma and currently in Phase I for Refractory Chronic Lymphocytic Leukemia (CLL)....
Sovleplenib acetate by Hutchison MediPharma for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura): Likelihood of Approval
Sovleplenib acetate is under clinical development by Hutchison MediPharma and currently in Phase I for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic...
Sovleplenib acetate by Hutchison MediPharma for Mantle Cell Lymphoma: Likelihood of Approval
Sovleplenib acetate is under clinical development by Hutchison MediPharma and currently in Phase I for Mantle Cell Lymphoma. According to...
Sovleplenib acetate by Hutchison MediPharma for Marginal Zone B-cell Lymphoma: Likelihood of Approval
Sovleplenib acetate is under clinical development by Hutchison MediPharma and currently in Phase I for Marginal Zone B-cell Lymphoma. According...
Sovleplenib acetate by Hutchison MediPharma for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval
Sovleplenib acetate is under clinical development by Hutchison MediPharma and currently in Phase I for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According...